AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20195587 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiral method (sum of enantiomers)
Number of subjects: 0
Study 20195587 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiral method (S-ibuprofen)
Number of subjects: 0
Study 20195587 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiral method (R-ibuprofen)
Number of subjects: 0
Study 18054932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (0.25 mg)
Number of subjects: 61
Study 18054932 — intervention group
Group type: COMPARATOR
Intervention: No cetrorelix (group I)
Number of subjects: 61
Study 16779569 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard trabeculectomy (Group 1)
Number of subjects: 64
Study 16779569 — intervention group
Group type: EXPERIMENTAL
Intervention: Releasable suture trabeculectomy (Group 2)
Number of subjects: 64
Study 16779569 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 64
Study 12824908 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 50 mg/day
Number of subjects: 244
Study 12824908 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg/day
Number of subjects: 244
Study 10547556 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of doxorubicin or epirubicin after TUR
Number of subjects: 1732
Study 10547556 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 1732
Study 10547556 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy
Number of subjects: 1732
Study 8708495 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol delivered by metered-dose inhaler (MDI) with paper spacer
Number of subjects: 30
Study 8708495 — intervention group
Group type: COMPARATOR
Intervention: Procaterol delivered by metered-dose inhaler (MDI) without spacer
Number of subjects: 30
Study 8708495 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol delivered by MDI with paper spacer
Number of subjects: 30
Study 1928683 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anaesthetic using infusion technique
Number of subjects: 40
Study 1928683 — intervention group
Group type: COMPARATOR
Intervention: Propofol anaesthetic using repeat bolus technique
Number of subjects: 40
Study 7133972 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of pirprofen
Number of subjects: 195
Study 7133972 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg of pirprofen
Number of subjects: 195
Study 7133972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 31912958 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose carbon monoxide inhalation (1.2 ml/kg for men; 1.0 ml/kg for women)
Number of subjects: 11
Study 30412235 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrule period (July-December 2017)
Number of subjects: 17937
Study 30412235 — intervention group
Group type: COMPARATOR
Intervention: Baseline period (July-December 2016)
Number of subjects: 17937
Study 30412235 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall opioid prescribing
Number of subjects: 17937
Study 28257388 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot ultrasound-guided SSNB (10 mL ropivacaine 1%)
Number of subjects: 168
Study 28257388 — intervention group
Group type: COMPARATOR
Intervention: Interscalene brachial plexus block (ISB) (20 mL ropivacaine 0.75%)
Number of subjects: 168
Study 25413170 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Rehabilitation Intervention (ERI)
Number of subjects: 184
Study 25413170 — intervention group
Group type: COMPARATOR
Intervention: Brief Education Intervention (BEI)
Number of subjects: 184
Study 25157767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m), Carboplatin (AUC 6), Bevacizumab (15 mg/kg) administered on day 1 of each 21-day cycle for up to six cycles, followed by maintenance pemetrexed and bevacizumab.
Number of subjects: 57
Study 22029398 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim Methadone (IM; supervised methadone with emergency counseling for the first 4 months)
Number of subjects: 230
Study 22029398 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Methadone (SM; with routine counseling)
Number of subjects: 230
Study 22029398 — intervention group
Group type: EXPERIMENTAL
Intervention: Restored Methadone (RM; routine counseling with smaller case-loads)
Number of subjects: 230
Study 22029398 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim Methadone (IM)
Number of subjects: 230
Study 22029398 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Methadone (SM)
Number of subjects: 230
Study 22029398 — intervention group
Group type: EXPERIMENTAL
Intervention: Restored Methadone (RM)
Number of subjects: 230
Study 22029398 — intervention group
Group type: COMPARATOR
Intervention: All groups (IM, SM, RM)
Number of subjects: 230
Study 19240178 — intervention group
Group type: EXPERIMENTAL
Intervention: High expression of MRP8
Number of subjects: 50
Study 19240178 — intervention group
Group type: EXPERIMENTAL
Intervention: MRP8-transfected LLC-PK1 cells
Number of subjects: 50
Study 19240178 — intervention group
Group type: EXPERIMENTAL
Intervention: MRP8-enriched membrane vesicles
Number of subjects: 50
Study 19240178 — intervention group
Group type: EXPERIMENTAL
Intervention: MRP8-transfected cells
Number of subjects: 50
Study 17326056 — intervention group
Group type: EXPERIMENTAL
Intervention: B-cell subtype NHL
Number of subjects: 587
Study 17326056 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell subtype NHL
Number of subjects: 587
Study 17326056 — intervention group
Group type: EXPERIMENTAL
Intervention: B-cell NHL with HBV infection
Number of subjects: 587
Study 17326056 — intervention group
Group type: COMPARATOR
Intervention: B-cell NHL
Number of subjects: 587
Study 15044641 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.25 mg/kg IV every 12 hours for one week, then tapered)
Number of subjects: 146
Study 15044641 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 146
Study 11370826 — intervention group
Group type: EXPERIMENTAL
Intervention: OND 32 mg for the first 24 hours, followed by 8 mg every 8 hours for the following four days, combined with dexamethasone 8 mg i.v. the first day and 8 mg p.o. for the following three days.
Number of subjects: 110
Study 11370826 — intervention group
Group type: COMPARATOR
Intervention: OND 8 mg every day for 4 days, combined with dexamethasone 8 mg i.v. and 8 mg p.o. for the following three days.
Number of subjects: 110
Study 9426013 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 312
Study 7798429 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline 500 mg, taken twice daily for 3 months
Number of subjects: 20
Study 7798429 — intervention group
Group type: EXPERIMENTAL
Intervention: Tab. Gugulipid (equivalent to 25 mg guggulsterone), taken twice daily for 3 months
Number of subjects: 20
Study 7798429 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 20
Study 7798429 — intervention group
Group type: EXPERIMENTAL
Intervention: Gugulipid
Number of subjects: 20
Study 3201130 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml antacid
Number of subjects: 15
Study 3201130 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 15
Study 30842037 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal so-tDCS bifrontaly at a frequency of 0.75 Hz
Number of subjects: 23
Study 30842037 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 23
Study 28742529 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric tuberculosis therapy
Number of subjects: 850
Study 28742529 — intervention group
Group type: COMPARATOR
Intervention: Preventive tuberculosis therapy
Number of subjects: 850
Study 25199496 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic mesh repair (Prolift™)
Number of subjects: 184
Study 25199496 — intervention group
Group type: COMPARATOR
Intervention: Native tissue repair
Number of subjects: 184
Study 22941391 — intervention group
Group type: EXPERIMENTAL
Intervention: Provox Vega Indwelling voice prosthesis
Number of subjects: 23
Study 21249529 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 47
Study 21249529 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 47
Study 21249529 — intervention group
Group type: EXPERIMENTAL
Intervention: Both toothbrush methods
Number of subjects: 47
Study 18972914 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative kinesic treatment (K)
Number of subjects: 38
Study 18972914 — intervention group
Group type: COMPARATOR
Intervention: Control group (NK)
Number of subjects: 38
Study 16554988 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg per hour SiV for 4 days
Number of subjects: 14
Study 16554988 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 14
Study 14712952 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EPI)
Number of subjects: 992
Study 14712952 — intervention group
Group type: COMPARATOR
Intervention: Continuous midwifery support (CMS)
Number of subjects: 992
Study 10730796 — intervention group
Group type: EXPERIMENTAL
Intervention: One-hour CBE retraining session
Number of subjects: 30
Study 10730796 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CBE retraining)
Number of subjects: 30
Study 8957211 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IMAL)
Number of subjects: 7
Study 8957211 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran sulphate adsorption (DSAL)
Number of subjects: 7
Study 8957211 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin‐induced extracorporeal LDL precipitation (HELP)
Number of subjects: 7
Study 1555059 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1.5 g/day)
Number of subjects: 16
Study 1555059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3505731 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 7.5-15.0 mg (mean elimination half-life approximately 2 h)
Number of subjects: 0
Study 3505731 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam 0.125-0.25 mg (mean elimination half-life approximately 5 h)
Number of subjects: 0
Study 3505731 — intervention group
Group type: COMPARATOR
Intervention: Placebo in bed
Number of subjects: 0
Study 31033786 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Lactobacillus rhamnosus) at a concentration of 5×10^9 CFU per sachet, administered twice daily by mouth.
Number of subjects: 0
Study 29055531 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy with agalsidase alfa
Number of subjects: 0
Study 27611038 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral paracetamol
Number of subjects: 50
Study 27611038 — intervention group
Group type: COMPARATOR
Intervention: Enteral paracetamol
Number of subjects: 50
Study 24685020 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa seeds powder
Number of subjects: 37
Study 24685020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 22991347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 2878
Study 22991347 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 2878
Study 21242601 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based physical activity program
Number of subjects: 540
Study 21242601 — intervention group
Group type: COMPARATOR
Intervention: No-PA control condition
Number of subjects: 540
Study 17081535 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 50 mg from days 5‐9 of the cycle
Number of subjects: 154
Study 17081535 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg three times a day
Number of subjects: 154
Study 17081535 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clomiphene citrate and metformin
Number of subjects: 154
Study 17081535 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 154
Study 17081535 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 154
Study 15910350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (group R)
Number of subjects: 60
Study 15910350 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine 0.2% (group L)
Number of subjects: 60
Study 12559939 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 1265
Study 12559939 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1265
Study 10393047 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (AZM) 500 mg/d
Number of subjects: 14
Study 10393047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8778430 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.51 of fluid (1 l normal saline and 1.51 5% dextrose)
Number of subjects: 45
Study 8778430 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 l of normal saline
Number of subjects: 45
Study 8778430 — intervention group
Group type: EXPERIMENTAL
Intervention: Free oral fluids
Number of subjects: 45
Study 2055080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine administration via instillation into the endotracheal tube (2 mg/kg, diluted to 10 mL)
Number of subjects: 32
Study 2055080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine administration via bronchoscope deep endotracheally
Number of subjects: 32
Study 2055080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine administration via bronchoscope into the right main bronchus
Number of subjects: 32
Study 2055080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine administration via bronchoscope into the right lower lobe bronchus
Number of subjects: 32
Study 6667814 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dl-carnitine infusion
Number of subjects: 6
Study 6667814 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6
Study 30076787 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide once weekly
Number of subjects: 33
Study 30076787 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide once daily
Number of subjects: 33
Study 29098323 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive responses to the three questions from the Michigan Neuropathy Screening Instrument (MNSI)
Number of subjects: 8463
Study 29098323 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive responses to all three questions from the MNSI
Number of subjects: 8463
Study 29098323 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of total number of affirmative responses to existing models
Number of subjects: 8463
Study 26873695 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically modifiable factors (SMF)
Number of subjects: 99
Study 26873695 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific factors (PSF)
Number of subjects: 99
Study 26873695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PSF and SMF
Number of subjects: 99
Study 25240966 — intervention group
Group type: COMPARATOR
Intervention: Practice change intervention involving local leadership, electronic medical record modification, educational meetings, outreach, practice change resources, and performance monitoring.
Number of subjects: 1989
Study 25240966 — intervention group
Group type: COMPARATOR
Intervention: Practice change intervention
Number of subjects: 1989
Study 22340561 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 317
Study 22340561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 20628336 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet gels
Number of subjects: 0
Study 20628336 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized bone matrix
Number of subjects: 0
Study 20628336 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic bone graft material (ceramics)
Number of subjects: 0
Study 20628336 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein (rhBMP-2)
Number of subjects: 0
Study 17681886 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal isometric exercise (40% to 50% of max) for 2 minutes with the dominant hand
Number of subjects: 14
Study 17681886 — intervention group
Group type: COMPARATOR
Intervention: Control (non-exercised hand)
Number of subjects: 14
Study 16135728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and colistin
Number of subjects: 47
Study 11821455 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cyclophosphamide, doxorubicin, and fluorouracil (CAF)
Number of subjects: 577
Study 11821455 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a prominent plexiform vascular pattern
Number of subjects: 577
Study 11821455 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of angiogenesis
Number of subjects: 577
Study 11821455 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiogenesis measures
Number of subjects: 577
Study 9809945 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (2 x 8 g/day)
Number of subjects: 39
Study 9809945 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (2 x 40 microg/day)
Number of subjects: 39
Study 9809945 — intervention group
Group type: COMPARATOR
Intervention: Control (no hemodynamically active treatment)
Number of subjects: 39
Study 7484753 — intervention group
Group type: EXPERIMENTAL
Intervention: rTPA therapy
Number of subjects: 42
Study 7484753 — intervention group
Group type: COMPARATOR
Intervention: Direct PTCA
Number of subjects: 42
Study 2702795 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (0.07 mg/kg) followed by isoproterenol (50 micrograms/min)
Number of subjects: 2
Study 2702795 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (0.07 mg/kg)
Number of subjects: 2
Study 2702795 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol sensitivity study
Number of subjects: 2
Study 209263 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose electrolyte solution
Number of subjects: 57
Study 209263 — intervention group
Group type: COMPARATOR
Intervention: Glucose electrolyte solution
Number of subjects: 57
Study 209263 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydration
Number of subjects: 57
Study 31120173 — intervention group
Group type: COMPARATOR
Intervention: Topical anti-wrinkle cream (AM cream) only
Number of subjects: 14
Study 31120173 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anti-wrinkle cream (AM cream) and topical evening DNA repair serum (PM serum)
Number of subjects: 14
Study 28533053 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV vaccine trial participants (n = 51)
Number of subjects: 111
Study 28533053 — intervention group
Group type: COMPARATOR
Intervention: Ad5+ participants (n = 60)
Number of subjects: 111
Study 26278124 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 10 mg weekly
Number of subjects: 52
Study 26278124 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid OMP (dexamethasone 2.5 mg, 5 tablets taken on 2 consecutive days weekly)
Number of subjects: 52
Study 26278124 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MTX and OMP)
Number of subjects: 52
Study 22825550 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA granules (nocturnal administration)
Number of subjects: 37
Study 22825550 — intervention group
Group type: COMPARATOR
Intervention: BCAA granules (daytime administration)
Number of subjects: 37
Study 21856481 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (intravenously for 2, 24, or 72 hours)
Number of subjects: 45
Study 21856481 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (higher plasma concentrations)
Number of subjects: 45
Study 21856481 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (high plasma concentrations)
Number of subjects: 45
Study 19257913 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term enhanced infection control support
Number of subjects: 565
Study 19257913 — intervention group
Group type: COMPARATOR
Intervention: Control group (no enhanced infection control support)
Number of subjects: 565
Study 16702892 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 16
Study 16702892 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg diazepam
Number of subjects: 16
Study 16702892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15364842 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosaic (M) aortic valve replacement
Number of subjects: 100
Study 15364842 — intervention group
Group type: COMPARATOR
Intervention: Perimount (P) aortic valve replacement
Number of subjects: 100
Study 15364842 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Mosaic and Perimount aortic valve replacements
Number of subjects: 100
Study 11216075 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 6800
Study 11216075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6800
Study 9144042 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium-based toothpaste
Number of subjects: 120
Study 9144042 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-based toothpaste
Number of subjects: 120
Study 9144042 — intervention group
Group type: COMPARATOR
Intervention: Fluoride toothpaste
Number of subjects: 120
Study 8203688 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric services plus early intervention services (intervention group)
Number of subjects: 985
Study 8203688 — intervention group
Group type: COMPARATOR
Intervention: Pediatric follow-up and referral (follow-up only group)
Number of subjects: 985
Study 3607576 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride (14 mg/kg)
Number of subjects: 32
Study 3607576 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine (0.56 mg/kg)
Number of subjects: 32
Study 31565828 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 15
Study 31565828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 28303751 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing treatment
Number of subjects: 97
Study 28303751 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing levels of all three peptides (n = 28)
Number of subjects: 97
Study 28303751 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing levels of one or two peptides (n = 59)
Number of subjects: 97